Dalzanemdor

DB21549InvestigationalSmall molecule

Dalzanemdor is a small molecule drug. Dalzanemdor is under investigation in clinical trial NCT05655520 (A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease). Dalzanemdor... Dalzanemdor has a monoisotopic molecular weight of 456.32 Da.

Mechanism: Pharmacologically active on NMDA receptor
Curator reviewed
Formula / weight: C₂₇H₄₃F₃O₂ · 456.634 g/mol (avg)
Code names: SAGE-718

Resolves to

Compound

UNII8ENS5K3JW8CAS1629853-48-0ChEMBLCHEMBL5095095

Structure

InChIKeyBVBRUQYHUXKZMQ-JNVAYQLDSA-NSMILES[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@](C)(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@](C)(O)C(F)(F)F

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Dalzanemdor, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account